pyrroles has been researched along with lenalidomide in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (42.86) | 29.6817 |
| 2010's | 8 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cooney, MM; Remick, SC; Vogelzang, NJ | 2 |
| Curtiss, FR | 1 |
| Hussar, DA | 1 |
| Alexander, HR; Blansfield, JA; Caragacianu, D; Libutti, SK; Lorang, D; Morita, SY; Muller, G; Royal, RE; Schafer, P; Stirling, D; Tangrea, MA | 1 |
| Lin, TS | 1 |
| Anderson, KC; Chauhan, D; Ciccarelli, B; Palladino, MA; Richardson, PG; Singh, AV | 1 |
| Goldschmidt, H; Moehler, T | 1 |
| Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES | 1 |
| Espinosa, E; González, R; Merino, M; Pinto, A | 1 |
| Fiedler, W; Wellbrock, J | 1 |
| Abe, M; Fujii, S | 1 |
| Beck, R; Burris, HA; Fandi, A; Garcia, JA; Infante, JR; Jungnelius, U; Li, S; Redman, B; Rini, B | 1 |
| Moreau, P; Rajkumar, SV | 1 |
7 review(s) available for pyrroles and lenalidomide
| Article | Year |
|---|---|
Promising systemic therapy for renal cell carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Drug Administration Schedule; Epothilones; Erlotinib Hydrochloride; Humans; Indoles; Kidney Neoplasms; Lenalidomide; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide | 2005 |
Novel agents for the treatment of advanced kidney cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Epothilones; Gefitinib; Humans; Indoles; Kidney Neoplasms; Lenalidomide; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide | 2004 |
Novel agents in chronic lymphocytic leukemia: efficacy and tolerability of new therapies.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Flavonoids; Humans; Indoles; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Maximum Tolerated Dose; Nitrogen Mustard Compounds; Piperidines; Pyrroles; Thalidomide; Thionucleotides; Treatment Outcome | 2008 |
Therapy of relapsed and refractory multiple myeloma.
Topics: Adrenal Cortex Hormones; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lactones; Lenalidomide; Middle Aged; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Secondary Prevention; Thalidomide | 2011 |
Novel molecular targeted therapies for refractory thyroid cancer.
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat | 2012 |
Antiangiogenic agents and endothelin antagonists in advanced castration resistant prostate cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Atrasentan; Benzenesulfonates; Castration; Drug Resistance, Neoplasm; Endothelin Receptor Antagonists; Endothelins; Humans; Indoles; Lenalidomide; Male; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Pyrrolidines; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A | 2011 |
Clinical experience with antiangiogenic therapy in leukemia.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Humans; Indoles; Lenalidomide; Leukemia; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sorafenib; Staurosporine; Sunitinib; Thalidomide; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2011 |
1 trial(s) available for pyrroles and lenalidomide
| Article | Year |
|---|---|
A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Pyrroles; Sunitinib; Thalidomide; Treatment Outcome | 2014 |
6 other study(ies) available for pyrroles and lenalidomide
| Article | Year |
|---|---|
Pharmacy benefit spending on oral chemotherapy drugs.
Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents; Benzamides; Benzenesulfonates; Capecitabine; Dasatinib; Deoxycytidine; Drug Costs; Employer Health Costs; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Health Benefit Plans, Employee; Humans; Imatinib Mesylate; Indoles; Insurance, Pharmaceutical Services; Lenalidomide; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Prescription Fees; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Thiazoles; United States | 2006 |
New drugs 07, part I.
Topics: Abatacept; Acetanilides; Alprostadil; Anidulafungin; Antidiuretic Hormone Receptor Antagonists; Antifungal Agents; Antineoplastic Agents; Arabinonucleosides; Benzazepines; Benzenesulfonates; Drug Approval; Drug Interactions; Drug Monitoring; Drug Therapy; Echinocandins; Fatty Acids; Humans; Hypoglycemic Agents; Immunoconjugates; Immunosuppressive Agents; Indoles; Insulin; Insulin Detemir; Insulin, Long-Acting; Intercellular Signaling Peptides and Proteins; Lenalidomide; Lubiprostone; Niacinamide; Patient Education as Topic; Peptides, Cyclic; Phenylurea Compounds; Piperazines; Pyridines; Pyrroles; Ranolazine; Sorafenib; Sunitinib; Thalidomide; United States | 2007 |
Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cyclophosphamide; Endothelial Cells; Female; Fluorescent Antibody Technique; Humans; Indoles; Lenalidomide; Mice; Neoplasms, Experimental; Neovascularization, Pathologic; Pyrroles; Rats; Sunitinib; Thalidomide; Xenograft Model Antitumor Assays | 2008 |
Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Division; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Humans; In Vitro Techniques; Lactones; Lenalidomide; Mice; Mice, SCID; Multiple Myeloma; Proteasome Inhibitors; Pyrroles; Thalidomide; Xenograft Model Antitumor Assays | 2010 |
[Molecular targeting agents for multiple myeloma].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Glycine; Histone Deacetylases; Humans; Immunologic Factors; Lactones; Lenalidomide; Molecular Targeted Therapy; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Pyrazines; Pyrroles; Thalidomide | 2012 |
Multiple myeloma--translation of trial results into reality.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boron Compounds; Bortezomib; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Cyclic N-Oxides; Drug Approval; Drug Discovery; Glycine; Humans; Indolizines; Lactones; Lenalidomide; Multiple Myeloma; Oligopeptides; Practice Guidelines as Topic; Pyridinium Compounds; Pyrroles; Thalidomide | 2016 |